Nivolumab and Ipilimumab Well-tolerated, Active in Metastatic Renal Cell Carcinoma

Share this content:
Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.
Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.

According to a study published in the Journal of Clinical Oncology, combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC).1

Previous studies show that combining nivolumab, a PD-1 inhibitor, and ipilimumab, a CTLA-4 inhibitor, leads to improved outcomes in metastatic melanoma and lung cancer. The evidence from these studies led the authors to investigate the potential benefit of the combination in mRCC.

In the phase 1, dose-escalation CheckMate-016 study (ClinicalTrials.gov Identifier: NCT01472081), investigators randomly assigned patients into 3 arms: nivolumab 3mg/kg plus ipilimumab 1mg/kg (N3I1), nivolumab 1mg/kg plus ipilimumab 3mg/kg (N1I3), or nivolumab 3mg/kg plus ipilimumab 3mg/kg (N3I3).

Each treatment was administered every 3 weeks for up to 4 doses intravenously (IV) followed by nivolumab 3mg/kg IV monotherapy every 2 weeks until disease progression or intolerable toxicity.

The N3I1 and N1I3 arms had a 40.4% overall response rates (ORR), with ongoing responses in 42.1% of patients in the N3I1 arm vs 36.8% in the N1I3 arm. The 2-year OS was 67.3% in the N3I1 arm vs 69.9% in the N1I3 arm.

Grade 3 or 4 adverse effects (AE) were reported in 38.3% in the N3I1 arm vs 61.7% of patients in the N1I3 arm.

RELATED: Restoring ASPP1 May Improve Outcomes in Clear Cell RCC

There were no confirmed responses in the N3I3 arm due to a high censoring percentage.

The study authors concluded that “the encouraging safety results in patients treated with the N3I1 combination regimen support the additional clinical investigation of N3I1 in a phase [3] study for patients with mRCC.”

Reference

  1. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkmate 016 study. J Clin Oncol. 2017 Jul 6. doi: 10.1200/JCO.2016.72.1985 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters